George Heidgerken, president and CEO of Boehringer Ingelheim Vetmedica, Inc., says the promotions of Bettington and Buller are indicative of the contributions they’ve made to the swine team and to the company over the last two years.

“Our swine business leads the industry in terms of product sales and technical service to our customers,” Heidgerken adds.

“Tim and Randy have played critical roles in that success through managing our brands and growing our business in the swine market.”

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Missouri), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Connecticut, and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.